Westend Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.62M Sell
8,286
-8,107
-49% -$8.22M 2.29% 23
2025
Q4
$17.6M Buy
+16,393
New +$15.7M 4.94% 5
2025
Q3
Sell
-2
Closed -$1.56K 265
2025
Q2
$1.56K Sell
2
-1
-33% -$777 ﹤0.01% 200
2025
Q1
$2.48K Sell
3
-15
-83% -$12.5K ﹤0.01% 191
2024
Q4
$13.9K Sell
18
-6,664
-100% -$5.52M ﹤0.01% 100
2024
Q3
$5.92M Sell
6,682
-7,714
-54% -$6.94M 2.03% 23
2024
Q2
$13.2M Buy
14,396
+38
+0.3% +$30.4K 4.62% 6
2024
Q1
$11.2M Buy
+14,358
New +$10.2M 4.33% 7

Other funds holding LLY

Westend Capital Management's LLY Position: Q1 2026 in Review

Westend Capital Management reduced its Eli Lilly (LLY) stake by 49% in Q1 2026, selling an estimated $8.22M and leaving 8,286 shares worth $7.62M. The position accounts for 2.29% of the portfolio, ranked #23.

Westend Capital Management first reported a position in LLY in Q1 2024 and has held it in 8 quarters since. The position peaked at $17.6M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Westend Capital Management held 8,286 shares of Eli Lilly worth $7.62M as of Q1 2026.
  • Westend Capital Management sold 8,107 Eli Lilly shares in Q1 2026, an estimated $8.22M.
  • Eli Lilly made up 2.29% of Westend Capital Management's portfolio in Q1 2026, its #23 holding.
  • Westend Capital Management first reported a position in Eli Lilly in Q1 2024 and has held it in 8 quarters since.
  • Westend Capital Management's Eli Lilly position peaked at $17.6M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Westend Capital Management's 13F filing for Q1 2026, filed 14 Apr 2026.